Trials / Completed
CompletedNCT00329693
Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide
A Randomised, Double-blind, Parallel Groups, Dose-finding, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide & Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian Hyperstimulation.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 182 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Female
- Age
- 21 Years – 37 Years
- Healthy volunteers
- Not accepted
Summary
Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.
Detailed description
No data to be entered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Norprolac | Placebo |
| DRUG | Norprolac | Quinagolide |
| DRUG | Norprolac | Quinagolide |
| DRUG | Norprolac | Quinagolide |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2007-08-01
- Completion
- 2008-05-01
- First posted
- 2006-05-25
- Last updated
- 2011-05-19
Locations
7 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT00329693. Inclusion in this directory is not an endorsement.